Top 20 of Multiple Myeloma

Article title # Publications/# Citations

Continuous cultures of fused cells secreting antibody of predefined specificity.

1975: GKöhler; CMilstein;

1618

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

1977: PArmitage; NEBreslow; DRCox; SVHoward; NMantel; KMcPherson; JPeto; RPeto; MCPike; PGSmith;

693

Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma.

1975: GBlobel; BDobberstein;

661

A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

1979: JFKearney; BLiesegang; ARadbruch; KRajewsky;

364

A better cell line for making hybridomas secreting specific antibodies.

1978: GKöhler; MShulman; CDWilde;

310

A phase 2 study of bortezomib in relapsed, refractory myeloma.

2003: JAdams; RAlexanian; MAlsina; KCAnderson; BBarlogie; JBerenson; DLEsseltine; THideshima; ... DIrwin; SJagannath; MKauffman; DKuter; SLee; SALimentani; RZOrlowski; SVRajkumar; PGRichardson; DPSchenkein; DSiegel; SSinghal; GSrkalovic;

307

Antibodies to major histocompatibility antigens produced by hybrid cell lines.

1977: GWButcher; GGalfre; JCHoward; SCHowe; CMilstein;

295

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

2005: Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators; KCAnderson; DBen-Yehuda; JBlade; MBoccadoro; ALBoral; JCavenagh; WSDalton; ... DLEsseltine; TFacon; HGoldschmidt; JLHarousseau; DIrwin; SLonial; JBPorter; DReece; PGRichardson; JFSan-Miguel; DSchenkein; MWSchuster; PSonneveld; EAStadtmauer;

282

B lineage--specific interactions of an immunoglobulin enhancer with cellular factors in vivo.

1985: GMChurch; AEphrussi; WGilbert; STonegawa;

280

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

2011: KCAnderson; PLBergsagel; JEBradner; MChesi; JEDelmore; IMGhobrial; TGilpatrick; WCHahn; ... TPHeffernan; GCIssa; HMJacobs; EKastritis; ALKung; MELemieux; MRMcKeown; CSMitsiades; RMParanal; JQi; PBRahl; PGRichardson; ACSchinzel; JShi; CRVakoc; RAYoung;

279

Preparation of monoclonal antibodies: strategies and procedures.

1981: GGalfre; CMilstein;

270

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

1999: RCatlett-Falcone; GCiliberto; WSDalton; JLFernandez-Luna; RJove; THLandowski; ALevitzki; LMoscinski; ... GNuñez; MMOshiro; RSavino; JTurkson;

252

Initial genome sequencing and analysis of multiple myeloma.

2011: MAdli; GJAhmann; KCAnderson; KGArdlie; DAuclair; ABaker; PLBergsagel; BEBernstein; ... JPBrunet; JCarpten; MAChapman; KCibulskis; YDrier; RFonseca; SBGabriel; LAGarraway; GGetz; TRGolub; WCHahn; CLHarview; CCHofmeister; SJagannath; AJJakubowiak; JJKeats; AKrishnan; ESLander; MSLawrence; JLevy; TLiefeld; SLonial; SMahan; MMeyerson; BMfuko; SMonti; ROnofrio; LMPerkins; TJPugh; SVRajkumar; AHRamos; ACSchinzel; DSSiegel; ASivachenko; CSougnez; AKStewart; JTrent; STrudel; RVij; DVoet; WWinckler; TZimmerman;

237

International uniform response criteria for multiple myeloma.

2006: International Myeloma Working Group; RAlexanian; KAnderson; MAttal; BBarlogie; MBeksac; ABelch; JBlade; ... MBoccadaro; MCavo; JCrowley; MDimopoulos; BGDurie; GGahrton; MGertz; JLHarousseau; DJoshua; RKyle; HLudwig; GMerlini; JSMiguel; GMorgan; RPowles; SVRajkumar; PRichardson; KShimizu; PSonneveld; PTosi; GTricot; ITuresson; DVesole; JWestin;

229

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

2003: BBarlogie; YMa; ERasmussen; JDShaughnessy; ETian; RWalker; FZhan;

223

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

2007: GAhmann; ABaker; MBarrett; PLBergsagel; EBraggio; LABrents; LBruhn; BBryant; ... JCarpten; MChesi; WJChng; ADispenzieri; HFogle; RFonseca; PGreipp; THenry; JJKeats; SKumar; CMancini; GMulligan; TPrice-Troska; RSchop; MSebag; CXShi; AKStewart; RTiedemann; JTrent; RValdez; SVan Wier; YXZhu;

221

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

2007: CMAnnunziata; BBarlogie; WBellamy; LDang; SDave; REDavis; YDemchenko; AGabrea; ... IHanamura; EMHurt; WMKuehl; GLenz; MSantra; JDShaughnessy; LMStaudt; OStephens; BTan; DRWilliams; GWright; WXiao; FZhan; HZhao;

219

Improved survival in multiple myeloma and the impact of novel therapies.

2007: FKBuadi; DDingli; ADispenzieri; MAGertz; PRGreipp; SRHayman; SKKumar; RAKyle; ... MQLacy; JALust; SVRajkumar; SJRussell; SRZeldenrust;

211

Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility.

1987: DBaltimore; MLenardo; JWPierce;

210

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001: JAdams; KCAnderson; DChauhan; PJElliott; THideshima; VJPalombella; PRichardson;

210